GPCM
ALXA

Granite Point Capital Management’s Alexza Pharmaceuticals Inc ALXA Stock Holding History

Granite Point Capital Management’s Portfolio ALXA Stock Details ALXA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-16,574
Closed -$78K – 128
2013
Q4 		$78K Buy
+16,574
New +$81.3K 0.01% 102

Other funds holding ALXA

LPA
Lansdowne Partners Austria Vienna, Austria $29M AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Granite Point Capital Management's ALXA Position: Q1 2014 in Review

Granite Point Capital Management sold out of Alexza Pharmaceuticals Inc (ALXA) in Q1 2014, closing a stake of 16,574 shares — an estimated $78K sold.

Granite Point Capital Management first reported a position in ALXA in Q4 2013 and held it in 1 quarter. The position peaked at $78K in Q4 2013. 45 funds tracked by Wall St. Rank hold ALXA as of Q1 2014.

  • Granite Point Capital Management reported no remaining Alexza Pharmaceuticals Inc position as of Q1 2014 after selling out during the quarter.
  • Granite Point Capital Management sold 16,574 Alexza Pharmaceuticals Inc shares in Q1 2014, an estimated $78K.
  • Granite Point Capital Management first reported a position in Alexza Pharmaceuticals Inc in Q4 2013 and held it in 1 quarter.
  • Granite Point Capital Management's Alexza Pharmaceuticals Inc position peaked at $78K in Q4 2013.
  • 45 funds tracked by Wall St. Rank held Alexza Pharmaceuticals Inc as of Q1 2014.

Based on Granite Point Capital Management's 13F filing for Q1 2014, filed 14 May 2014.